Buy Cefuroxime online in the UK – fast delivery from a trusted pharmacy

Cefuroxime, a second-generation cephalosporin introduced in the 1980s, remains among the most widely prescribed antibiotics for community‑acquired respiratory and skin infections. It exerts bactericidal activity by inhibiting cell wall synthesis through binding to penicillin‑binding proteins, producing time‑dependent killing. Available as both oral (cefuroxime axetil) and parenteral formulations, the drug achieves systemic exposure suitable for treatment of a broad range of susceptible pathogens. Oral absorption of the axetil prodrug improves with food, while parenteral administration provides reliable serum concentrations and tissue penetration. Cefuroxime is primarily renally cleared and requires dose adjustment in renal impairment to avoid accumulation and toxicity.

In addition to its spectrum against common Gram‑positive cocci (including susceptible Streptococcus species) and many Gram‑negative organisms, cefuroxime covers Haemophilus influenzae and Moraxella catarrhalis and some Enterobacterales such as Escherichia coli and Klebsiella spp. Its activity against beta‑lactamase–producing strains varies by organism and local resistance patterns. Notably, cefuroxime lacks reliable activity against methicillin‑resistant Staphylococcus aureus and most anaerobes; these limitations guide empiric therapy and the need for culture data when available.

What it is used for

Cefuroxime is indicated for mild to moderate infections caused by susceptible organisms, including acute otitis media, acute bacterial sinusitis, community‑acquired pneumonia, and uncomplicated bronchitis. It is also employed for diverse skin and soft tissue infections, including cellulitis and minor wound infections, when a cephalosporin is considered appropriate therapy. In women, cefuroxime can be used for certain gynecologic infections caused by susceptible bacteria. For urinary tract infections, cefuroxime provides an effective oral or parenteral option when local pathogens are susceptible and oral therapy is preferred.

Outpatient management often relies on oral cefuroxime axetil, while parenteral cefuroxime (sodium salt) is reserved for moderate to severe disease or when rapid systemic exposure is required. Dosing decisions depend on the infection site, severity, patient age, and renal function, with adjustments necessary in renal impairment to maintain efficacy and minimize adverse effects. Clinicians should consider local resistance data and patient allergy history when selecting therapy.

Contraindications and precautions

Contraindications include known hypersensitivity to cefuroxime, other cephalosporins, or any beta‑lactam antibiotics. A history of anaphylaxis or severe hypersensitivity reactions to beta‑lactams is a clear contraindication due to potential cross‑reactivity. Caution is advised in patients with a prior penicillin allergy, particularly if the reaction was severe, as cross‑reactivity, although not universal, can occur.

Precautions include renal impairment, as cefuroxime is primarily eliminated by the kidneys; dose adjustments are often warranted in moderate to severe impairment to prevent drug accumulation and central nervous system or gastrointestinal toxicity. Prolonged therapy necessitates monitoring for superinfection and secondary resistant organisms. Clinicians should remain vigilant for signs of Clostridioides difficile infection in patients experiencing diarrhea during or after antibiotic therapy.

Pregnancy and lactation require judicious consideration. Cefuroxime crosses the placenta in small amounts and should be used during pregnancy only if clearly indicated after benefit‑risk assessment. It is excreted into breast milk; if therapy is required during lactation, the potential impact on the infant should be weighed against maternal benefit. In pediatric populations, dosing is carefully age‑ and weight‑based; safety in neonates and preterm infants requires consideration of immature renal function.

Side effects by frequency

Common adverse events (occurring with relatively higher frequency) include gastrointestinal disturbances such as diarrhea, nausea, vomiting, abdominal discomfort, and mild dyspepsia. Patients may also experience rash, pruritus, or localized injection‑site reactions with parenteral administration. Headache and transient elevations in liver enzymes have been reported. These events are generally reversible with standard supportive care or dose adjustment.

Uncommon events (0.1–1%) include hypersensitivity skin manifestations such as urticaria and drug‑induced rashes, as well as eosinophilia or mild leukopenia. Transient renal function tests abnormalities may rarely occur, especially in patients with preexisting renal compromise or concomitant nephrotoxic therapies. Candidal infections at mucosal sites can occur due to disruption of normal flora.

Rare events (<0.1%) include serious hypersensitivity reactions such as anaphylaxis or angioedema. Severe cutaneous adverse reactions, including Stevens‑Johnson syndrome or toxic epidermal necrolysis, have been reported in temporal association with beta‑lactams in rare cases. Cholestatic jaundice, cholestasis, hepatitis, and, very infrequently, other severe hepatic or hematologic abnormalities may occur. Seizures have been reported in patients with predisposing conditions or very high doses.

Notable postmarketing observations include Clostridioides difficile infection presenting with diarrhea ranging from mild to severe, which can occur with antibiotic exposure and requires appropriate diagnostic and therapeutic management. Overall, the incidence of serious adverse events is low, but vigilance is advised during extended therapy or in vulnerable populations.

Interactions with other substances

Probenecid, used to prolong the half‑life of certain drugs by reducing renal clearance, can increase cefuroxime serum concentrations and prolong exposure; concomitant use should be monitored for enhanced effects or toxicity.

Absorption of oral cefuroxime axetil can be reduced when administered with absorbing‑disrupting agents such as aluminum or magnesium‑containing antacids, sucralfate, or iron preparations. If combination therapy is necessary, dosing should be separated by several hours to minimize interaction and preserve bioavailability.

Renal‑excreted antimicrobial agents and nephrotoxic drugs, including certain aminoglycosides and nonsteroidal anti‑inflammatory drugs, may have additive nephrotoxic risk when used with cefuroxime; careful assessment and monitoring of renal function are advisable in co‑therapy or prolonged courses. Coagulation parameters may be affected in some patients taking anticoagulants (eg, warfarin) due to the potential for antibiotic‑associated alterations in gut flora and vitamin K production; monitoring of prothrombin time or INR is prudent when therapy is combined with anticoagulants.

As with other beta‑lactams, cross‑reactivity with penicillins, while unlikely, has been described; a documented history of severe penicillin allergy warrants caution or alternative therapy. Overall, cefuroxime interactions are manageable with appropriate scheduling, dose adjustments, and clinical monitoring based on patient risk factors and concomitant medications.